Liminatus Pharma Inc Cl A (LIMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | |
| Operating Expenses | 2,968 | 3,330 |
| Operating Income | -2,968 | -3,330 |
| Interest Expense | 216 | 339 |
| Other Income | -7,023 | 123 |
| Pre-tax Income | -10,207 | -3,546 |
| Net Income Continuous | -10,207 | -3,546 |
| Net Income | $-10,207 | $-3,546 |
| EPS Basic Total Ops | -0.43 | -0.20 |
| EPS Basic Continuous Ops | -0.43 | -0.20 |
| EPS Diluted Total Ops | -0.43 | -0.20 |
| EPS Diluted Continuous Ops | -0.43 | -0.20 |
| EPS Diluted Before Non-Recurring Items | -0.17 | N/A |
| EBITDA(a) | $-2,966 | $-3,330 |